Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma
Dunne E, Fick C, Mastrogiacomo B, Tan K, Toumbacaris N, Vanstraelen S, Rocco G, Chaft J, Iyengar P, Gomez D, Adusumilli P, Park B, Isbell J, Bott M, Sihag S, Molena D, Huang J, Jones D. Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma. JTCVS Open 2024, 22: 458-469. PMID: 39780816, PMCID: PMC11704575, DOI: 10.1016/j.xjon.2024.09.030.Peer-Reviewed Original ResearchResection of lung adenocarcinomaMaximum standardized uptake valueDevelopment of brain metastasesBrain metastasesStandardized uptake valueNeoadjuvant therapyLung adenocarcinomaAssociated with developmentLymphovascular invasionTP53 mutationsUptake valueCumulative incidence of brain metastasesMarker of aggressive tumor biologyHighest maximum standardized uptake valueLack of extracranial metastasesIncidence of brain metastasesNext-generation sequencingPanel next-generation sequencingAssociated with better survivalStage III diseaseMedian Follow-UpAggressive tumor biologyBetter performance statusAssociated with brain metastasisStereotactic radiosurgerySequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
Ascierto P, Mandalà M, Ferrucci P, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Quaglino P, Lebbé C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzalez-Cao M, Minisini A, De Placido S, Sanmamed M, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mallardo D, Paone M, Vitale M, Melero I, Grimaldi A, Giannarelli D, Palmieri G, Dummer R, Sileni V. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma. NEJM Evidence 2024, 3: evidoa2400087. PMID: 39315864, DOI: 10.1056/evidoa2400087.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitionBrain metastasesBRAF/MEK inhibitorsArm BArm AProgressive diseaseCheckpoint inhibitionBrain metastases-free survivalImmune checkpoint inhibitor ipilimumabMetastases-free survival ratesDevelopment of brain metastasesCheckpoint inhibitor ipilimumabMetastases-free survivalUnresectable metastatic melanomaV600-mutant melanomaCheckpoint inhibitorsInhibitor ipilimumabMetastatic melanomaBRAF/MEK inhibitionArm CReviewed patientsBRAF/MEKThree-arm trialEncorafenibFollow-up
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply